Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q4 2025
Arcturus Therapeutics Holdings (ARCT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 3, 2026
Arcturus Therapeutics Holdings (ARCT) reported revenue of $7.2M for the fourth quarter 2025 (Q4 2025), -68% from a year earlier and -58% from the quarter before. Operating margin was -435.1%, net loss $29.1M (404.1% of revenue).
Arcturus Therapeutics Holdings, Q4 2025: revenue $7.2M (-68% year over year), operating margin -435.1%, net loss $29.1M, operating cash flow −$16.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | -58% | -68% |
| Operating profit | −$31.3M | — | — |
| Net earnings | −$29.1M | — | — |
| Operating cash flow | −$16.2M | — | — |
What changed
Revenue was $7.2M in Q4 2025, down 68% year over year and down 58% from the previous quarter. Grant was the largest line at 57% of revenue.
Operating costs exceeded revenue by $31.3M, an operating margin of -435.1%. Total costs fell 31% while revenue fell 68%. The fastest-growing cost line was General & admin (+13%). The quarter ended with a net loss of $29.1M, wider than the previous quarter's $13.4M loss.
Operating cash flow was −$16.2M. Non-cash charges added back $682K of depreciation and amortization and $6.8M of share-based compensation. Working capital and other items added $5.4M. Capital expenditures of −$88K exceeded it, leaving free cash flow of −$16.1M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the fourth quarter 2025?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $7.2M for the fourth quarter 2025 (Q4 2025), -68% from a year earlier and -58% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the fourth quarter 2025?
Operating loss was $31.3M (-435.1% of revenue) and net loss $29.1M.